World Front News

(WorldFrontNews Editorial):- Bangkok, Thailand Aug 22, 2023 (Issuewire.com) – DeepTek, a leading provider of AI-powered radiology solutions, is proud to announce that its revolutionary chest X-ray screening solution, GenkiTM, has received approval from the Thai Food and Drug Administration (FDA). GenkiTM leverages cutting-edge AI technology to classify scans as normal and abnormal along with further analyzing over 19 different chest pathologies. By automating the interpretation of chest X-rays, GenkiTM offers immense potential for improving medical diagnosis and treatment efficiency for lung diseases such as tuberculosis, pneumonia, lung cancer, and chronic pulmonary diseases, all of which pose significant health challenges globally.

DeepTek’s solutions have made a substantial impact across the Asia Pacific region serving over 400 customers including government bodies, public and private hospitals, imaging centers, and teleradiology companies. GenkiTM has already been serving as a lung health screening solution in India and the Philippines and has been instrumental in the ongoing TB Free initiatives in India, where over 300,000 individuals were screened, significantly increasing the detection rate of TB patients, and helping in early identification and timely patient care. Taking India, a step closer to a TB-free future!

More on World Front News Stories:

• Get 10% off Any Music Promotion from Music Promotion Club
• Get Grooving With the Queensland DJ Christian Krauter and His Incredibly Upbeat Releases
• Integrity Home Supply Celebrates Grand Opening of New Home Improvement Store in Philadelphia
• What are the Benefits of Press Release?
• Sarenadee Box, Recognized by BestAgents.us as a 2024 Top Agent

The solution’s effectiveness is backed by independent evaluations conducted by esteemed organizations like StopTB Partnership, Friends for International TB, and several others across the globe, which shows that the performance of AI is at par with human experts. 

DeepTek is actively collaborating with leading hospitals and medical institutions across Thailand to integrate its AI solutions into their existing radiology workflows. The seamless integration of its technology ensures that healthcare providers can benefit from the power of AI without disrupting their established processes, paving the way for widespread adoption and market expansion.

Commenting on the Thai FDA approval, Ajit Patil, Co-Founder of DeepTek, said “Thailand has gained a reputation for offering excellent medical resources and healthcare services by thinking ahead of time. The recent approval from the Thai regulatory body testifies to the readiness of the country to adopt AI into their healthcare services. We are happy to have partnered with leading healthcare providers in Thailand and be backed by Shimadzu Asia Pacific. We look forward to tapping vast opportunities in Thailand and beyond.”

About DeepTek

Incorporated in the U.S. in 2017, DeepTek is amongst very few Radiology AI start-ups, which has successfully established commercial adoption of AI technology in clinical practice-creating clear and quantifiable value for patients, hospitals, and radiologists. Our vision is to provide cutting-edge solutions powered by deep learning algorithms that will bridge the wide gap in the imaging sector. DeepTek.ai’s offerings touch several lives across India, Japan, Singapore, Thailand, Philippines, Nigeria, Kenya, and several other countries.

DeepTek.ai has a team of 200+ members with a unique mix of technology experts and radiologists and is supported by marquee equity partners like TATA Capital Healthcare Fund II and NTT DATA. For more information, visit www.deeptek.ai